Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 1.7x - 1.8x | 1.8x |
| Historical Pb Multiple | 1.1x - 2.0x | 1.8x |
| Fair Value | €3.46 - €3.82 | €3.64 |
| Upside | -18.3% - -9.7% | -14.0% |
| Benchmarks | - | Full Ticker |
| AstraZeneca PLC | - | LSE:AZN |
| Bayer Aktiengesellschaft | - | LSE:0P6S |
| Johnson & Johnson | - | LSE:0R34 |
| Perrigo Company plc | - | LSE:0Y5E |
| Sandoz Group AG | - | LSE:0SAN |
| Haleon plc | - | XTRA:H6D0 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| AZN | 0P6S | 0R34 | 0Y5E | 0SAN | H6D0 | |||
| LSE:AZN | LSE:0P6S | LSE:0R34 | LSE:0Y5E | LSE:0SAN | XTRA:H6D0 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 39.4% | NM- | -1.4% | NM- | NM- | 17.1% | ||
| 3Y CAGR | 297.5% | NM- | -7.5% | NM- | NM- | 1.2% | ||
| Latest Twelve Months | 22.8% | -4.3% | 27.8% | -20687.5% | -100.0% | 37.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 9.2% | -4.3% | 24.5% | -2.6% | 3.8% | 12.1% | ||
| Prior Fiscal Year | 13.0% | -6.2% | 15.6% | -0.1% | 0.8% | 9.3% | ||
| Latest Fiscal Year | 13.0% | -5.5% | 15.8% | -3.7% | 0.0% | 12.8% | ||
| Latest Twelve Months | 14.1% | -7.0% | 24.4% | -3.8% | 0.0% | 12.8% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 13.9% | -7.5% | 23.0% | -1.5% | 2.8% | 5.6% | ||
| Prior Fiscal Year | 15.6% | -8.2% | 18.3% | -0.1% | 0.9% | 6.4% | ||
| Latest Twelve Months | 19.8% | -9.6% | 29.4% | -3.6% | 0.0% | 8.8% | ||
| Next Fiscal Year | 31.0% | 13.1% | 33.4% | 9.5% | 15.7% | 10.1% | ||
| Two Fiscal Years Forward | 29.1% | 12.2% | 30.2% | 9.5% | 16.1% | 10.5% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 4.0x | 0.6x | 4.2x | 0.9x | 2.3x | 2.9x | ||
| Price / LTM EPS | 28.1x | -8.3x | 17.3x | -23.0x | NA | 22.9x | ||
| Price / Book | 5.3x | 0.8x | 4.8x | 0.9x | 3.0x | 2.0x | ||
| Price / Fwd Book | 4.5x | 0.7x | 4.6x | 0.8x | 2.6x | 2.0x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.8x | 3.0x | 5.3x | |||||
| Historical P/B Ratio | 1.1x | 1.8x | 2.0x | |||||
| Selected P/B Multiple | 1.7x | 1.8x | 1.8x | |||||
| (x) Book Value | 16,166 | 16,166 | 16,166 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | AZN | 0P6S | 0R34 | 0Y5E | 0SAN | H6D0 | |
| Value of Common Equity | 221,982 | 26,781 | 376,334 | 3,751 | 24,172 | 33,048 | |
| (/) Shares Outstanding | 1,550.7 | 982.4 | 2,406.1 | 137.5 | 430.7 | 8,984.5 | |
| Implied Stock Price | 143.15 | 27.26 | 156.41 | 27.28 | 56.12 | 3.68 | |
| FX Conversion Rate to Trading Currency | 1.34 | 1.00 | 1.00 | 1.00 | 1.25 | 0.87 | |
| Implied Stock Price (Trading Cur) | 106.62 | 27.26 | 156.41 | 27.28 | 44.79 | 4.23 | |
| Trading Currency | GBP | EUR | USD | USD | CHF | EUR | |
| FX Rate to Reporting Currency | 1.34 | 1.00 | 1.00 | 1.00 | 1.25 | 0.87 | |